Biote obtains exclusive option to acquire Nerelis Inc April 14, 2021 Biotie Therapies Corp. (Biotie) has announced that it has obtained an exclusive option to acquire Neurelis, Inc. (Neurelis), a private specialty pharmaceutical company based in San Diego, CA, focused on developing products for epilepsy and other disorders of the central nervous system (CNS). Neurelis’ lead product, NRL-1, is a proprietary intranasal formulation of diazepam delivered via an already marketed nasal sprayer. It is being developed to help patients with epilepsy who require intermittent use of diazepam to mana...